PMID- 31999937
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210518
IS  - 1840-4812 (Electronic)
IS  - 1512-8601 (Print)
IS  - 1512-8601 (Linking)
VI  - 20
IP  - 3
DP  - 2020 Aug 3
TI  - Circulating long noncoding RNAs H19 and GAS5 are associated with type 2 diabetes 
      but not with diabetic retinopathy: A preliminary study.
PG  - 365-371
LID - 10.17305/bjbms.2019.4533 [doi]
AB  - Recently, a wide range of biological and pathological roles of long noncoding 
      RNAs (lncRNAs) have been discovered. However, the potential role of circulating 
      lncRNAs H19 and GAS5 in type 2 diabetes mellitus (T2DM) and diabetic retinopathy 
      (DR) is not clear. Here, we assessed the plasma levels of H19 and GAS5 lncRNAs in 
      T2DM patients with/without DR and evaluated if H19 and GAS5 pre-treatment plasma 
      levels are a predictor of early response to a single aflibercept dose in DR 
      subgroup. Plasma lncRNA expression profiles of 119 T2DM patients (66 with DR and 
      53 without DR) and 110 healthy controls were determined by quantitative reverse 
      transcription PCR. The association of lncRNA expression profiles with clinical 
      features and aflibercept early response in DR patients was investigated. Relative 
      H19 expression levels were significantly increased in T2DM group (including DR 
      and non-DR subgroups) vs. controls, while GAS5 levels were decreased in T2DM 
      group (p < 0.001). There was no significant difference in H19 and GAS5 expression 
      levels between DR and non-DR subgroups. H19 and GAS5 expression profiles were not 
      significantly correlated with clinical parameters or response to aflibercept 
      therapy in DR subgroup. Our findings indicate that the circulating lncRNAs H19 
      and GAS5 may be associated with T2DM prevalence but may not have an important 
      diagnostic/prognostic role in DR or early response to aflibercept intravitreal 
      injection in DR patients. Large-scale transcriptomic studies are warranted to 
      validate our results and investigate other lncRNA candidates in T2DM.
FAU - Fawzy, Manal S
AU  - Fawzy MS
AD  - Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, 
      Suez Canal University, Ismailia, Egypt; Department of Biochemistry, Faculty of 
      Medicine, Northern Border University, Arar, Saudi Arabia.
FAU - Abdelghany, Ahmed A
AU  - Abdelghany AA
AD  - Department of Ophthalmology, Faculty of Medicine, Suez Canal University, 
      Ismailia, Egypt.
FAU - Toraih, Eman A
AU  - Toraih EA
AD  - Department of Surgery, School of Medicine, Tulane University, New Orleans, 
      Louisiana, USA; Department of Histology and Cell Biology (Genetics Unit), Faculty 
      of Medicine, Suez Canal University, Ismailia, Egypt.
FAU - Mohamed, Abeer M
AU  - Mohamed AM
AD  - Department of Clinical Pathology and Clinical Chemistry, Faculty of Medicine, 
      Sohag University, Sohag, Egypt; Department of Clinical Laboratory Sciences, 
      Al-Ghad International College for Applied Medical Sciences, Abha, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - Bosnia and Herzegovina
TA  - Bosn J Basic Med Sci
JT  - Bosnian journal of basic medical sciences
JID - 101200947
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/drug therapy/*genetics
MH  - Diabetic Retinopathy/drug therapy/*genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - RNA, Long Noncoding/blood/*genetics
MH  - Receptors, Vascular Endothelial Growth Factor/therapeutic use
MH  - Recombinant Fusion Proteins/therapeutic use
PMC - PMC7416173
COIS- Conflict of interest statement: The authors declare no conflict of interests
EDAT- 2020/01/31 06:00
MHDA- 2021/05/19 06:00
PMCR- 2020/08/01
CRDT- 2020/01/31 06:00
PHST- 2019/11/25 00:00 [received]
PHST- 2019/12/14 00:00 [accepted]
PHST- 2020/01/31 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
PHST- 2020/01/31 06:00 [entrez]
PHST- 2020/08/01 00:00 [pmc-release]
AID - BJBMS-20-365 [pii]
AID - 10.17305/bjbms.2019.4533 [doi]
PST - epublish
SO  - Bosn J Basic Med Sci. 2020 Aug 3;20(3):365-371. doi: 10.17305/bjbms.2019.4533.